Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

This retrospective study aimed at evaluating the prognostic impact of high serum levels of either the HER-2 extracellular domain (ECD) or the epidermal growth factor receptor (EGFR) ECD measured using two specific ELISAs in 221 patients with non-small-cell lung cancer (NSCLC) receiving conventional...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacot, W, Pujol, J-L, Boher, J-M, Lamy, P-J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409859/
https://www.ncbi.nlm.nih.gov/pubmed/15226769
http://dx.doi.org/10.1038/sj.bjc.6601987
Descripción
Sumario:This retrospective study aimed at evaluating the prognostic impact of high serum levels of either the HER-2 extracellular domain (ECD) or the epidermal growth factor receptor (EGFR) ECD measured using two specific ELISAs in 221 patients with non-small-cell lung cancer (NSCLC) receiving conventional therapy and 41 nonmalignant pulmonary diseases patients. It was not possible to discriminate between lung cancer and benign lung disease owing to the lack of sensitivity–specificity relationship of HER-2 and EGFR ECD levels. Neither HER-2 nor EGFR ECD specific levels were associated with a particular prognosis of NSCLC patients receiving conventional therapy.

Ejemplares similares